ADMA BIOLOGICS, INC. Subordinated Debt
ADMA BIOLOGICS, INC. (ADMA) had Subordinated Debt of $0 as of 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:SubordinatedDebt · last filed 2021-03-25
- 2020-12-31: Subordinated Debt $0.00.
- 2020-09-30: Subordinated Debt $14.93M.
- 2020-06-30: Subordinated Debt $14.93M.
- 2020-03-31: Subordinated Debt $14.92M.
| Period end | Subordinated Debt |
|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-03-25 |
| 2020-09-30 | $14.93M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $14.93M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $14.92M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $14.91M 10-K · filed 2021-03-25 |
| 2019-09-30 | $14.90M 10-Q · filed 2019-11-06 |
| 2018-12-31 | $14.87M 10-Q · filed 2019-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |